<div dir="ltr">Dear colleagues,<div>is now online the call for Papers for a special issue on <span style="color:rgb(0,0,0);font-family:"Minion W08 Bold",minionblackadditional">EEG-Based Biomarkers for Dementia, published on </span>Disease Markers (Impact Factor 2.348) <span style="color:rgb(0,0,0);font-family:"Minion W08 Bold",minionblackadditional"> </span><font color="#000000" face="Minion W08 Bold, minionblackadditional"><a href="https://www.hindawi.com/journals/dm/si/872673/cfp/">https://www.hindawi.com/journals/dm/si/872673/cfp/</a></font></div><div><br></div><div><br><h4 style="border-width:0px 0px 1px;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:rgb(204,204,204);border-left-color:initial;font-family:"Minion W08 Bold",minionblackadditional;font-weight:normal;margin:24px 0px 12px;outline:none 0px;padding:0px 0px 1px;font-size:18px;line-height:22px;color:rgb(153,153,153)">Call for Papers</h4><p style="border:0px none;font-family:"Minion W08 Regular_1167271",Times;margin:12px 0px;outline:none 0px;padding:0px;line-height:20px;color:rgb(0,0,0);font-size:17px">The diagnosis and treatment of dementia has become a growing and worrying public health problem in both developed and developing countries. Research to identify reliable markers is very active and there is currently a consensus among scientists that a presymptomatic variable duration stage is characteristic of most dementias. Starting treatment only when the symptoms appear is probably too late to have full effectiveness of medications able to control disease progression. Consequently, there is a pressing need for low-cost, high-sensitive, and high-specific biomarkers for early identification of individuals at risk of developing dementia within a few years. The analysis of electroencephalographic signals is potentially one of the best candidates because EEG equipment is cheap and safe. More importantly, EEG markers may probe the neurophysiological “reserve” in patients with dementing disorders. It was defined as the residual ability of the brain to ensure the synchronization of neural activity at different spatial scales and frequencies from small cellular populations to large regions and the coordination of that synchronization across subcortical and cortical neural networks. Unfortunately, the vast majority of the scientific community does not accept EEG signal analysis as a reliable topographic marker for dementia, although a growing number of published studies show the opposite. Such wary attitude could be due to the fact that even though there is a wide range of innovative approaches to signal analysis; so far there has been little effort to explore their complementarity and integrate them all in a stronger and more reliable biomarker.</p><p style="border:0px none;font-family:"Minion W08 Regular_1167271",Times;margin:12px 0px;outline:none 0px;padding:0px;line-height:20px;color:rgb(0,0,0);font-size:17px">To step up the discussion on EEG markers and dementia, the present special issue will solicit manuscripts reporting studies aimed at advancing the field of EEG-based biomarkers along different paths. Submissions related to the assessment of the neurophysiological “reserve” are especially welcome, mainly those markers derived from resting state EEG rhythms. The submission of studies aiming to probe the cortical neural synchronization/desynchronization at given frequency bands and reflecting neurophysiological mechanisms underpinning local cortical arousal in quiet wakefulness and vigilance will be particularly appreciated. Likewise, manuscripts supporting the importance of dementia biomarkers based on task-related EEG are also welcome, as well as those exploring functional cortical connectivity in both resting state and task-related EEG. Finally, submission of review articles describing the current state of the art is highly encouraged and even judiciously designed studies show negative results.</p><p style="border:0px none;font-family:"Minion W08 Regular_1167271",Times;margin:12px 0px;outline:none 0px;padding:0px;line-height:20px;color:rgb(0,0,0);font-size:17px">Potential topics include but are not limited to the following:</p><ul class="gmail-li_special" style="border:0px none;font-family:"Minion W08 Regular_1167271",Times;margin:0px 0px 0px 24px;outline:none 0px;padding:0px;list-style:none outside none;color:rgb(0,0,0);font-size:17px"><li style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none 0px;padding:0px 0px 0px 12px;text-align:left;list-style-type:none;background-repeat:no-repeat;background-position:0% 7px;background-image:url("../images/green_arrow.svg");background-size:6px 8px">New dementia EEG biomarkers</li><li style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none 0px;padding:0px 0px 0px 12px;text-align:left;list-style-type:none;background-repeat:no-repeat;background-position:0% 7px;background-image:url("../images/green_arrow.svg");background-size:6px 8px">Innovations in low-cost EEG measurement for dementia diagnostics</li><li style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none 0px;padding:0px 0px 0px 12px;text-align:left;list-style-type:none;background-repeat:no-repeat;background-position:0% 7px;background-image:url("../images/green_arrow.svg");background-size:6px 8px">Unsupervised or semisupervised extraction of EEG biomarkers</li><li style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none 0px;padding:0px 0px 0px 12px;text-align:left;list-style-type:none;background-repeat:no-repeat;background-position:0% 7px;background-image:url("../images/green_arrow.svg");background-size:6px 8px">Multimodal (EEG + other modalities) biomarkers</li><li style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none 0px;padding:0px 0px 0px 12px;text-align:left;list-style-type:none;background-repeat:no-repeat;background-position:0% 7px;background-image:url("../images/green_arrow.svg");background-size:6px 8px">Biomarkers of MCI progression to AD</li><li style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none 0px;padding:0px 0px 0px 12px;text-align:left;list-style-type:none;background-repeat:no-repeat;background-position:0% 7px;background-image:url("../images/green_arrow.svg");background-size:6px 8px">Confounding factors in EEG biomarker research</li><li style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none 0px;padding:0px 0px 0px 12px;text-align:left;list-style-type:none;background-repeat:no-repeat;background-position:0% 7px;background-image:url("../images/green_arrow.svg");background-size:6px 8px">Biomarker-based neurofeedback for mental training</li><li style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none 0px;padding:0px 0px 0px 12px;text-align:left;list-style-type:none;background-repeat:no-repeat;background-position:0% 7px;background-image:url("../images/green_arrow.svg");background-size:6px 8px">EEG-based correlates of treatment outcome/progress prediction</li><li style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none 0px;padding:0px 0px 0px 12px;text-align:left;list-style-type:none;background-repeat:no-repeat;background-position:0% 7px;background-image:url("../images/green_arrow.svg");background-size:6px 8px">Multimarker strategy (EEG, circulating biomarkers, and clinical variables) for dementia</li><li style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none 0px;padding:0px 0px 0px 12px;text-align:left;list-style-type:none;background-repeat:no-repeat;background-position:0% 7px;background-image:url("../images/green_arrow.svg");background-size:6px 8px">Diagnostic role and predictive value of EEG and other imaging modalities for dementia</li></ul><p style="border:0px none;font-family:"Minion W08 Regular_1167271",Times;margin:12px 0px;outline:none 0px;padding:0px;line-height:20px;color:rgb(0,0,0);font-size:17px">Authors can submit their manuscripts through the Manuscript Tracking System at<a href="https://mts.hindawi.com/submit/journals/dm/ebd/" style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none;padding:0px;text-decoration-line:none;color:rgb(65,139,52)">https://mts.hindawi.com/submit/journals/dm/ebd/</a>.</p><div class="gmail-c4p_table" style="border:0px none;font-family:"Minion W08 Regular_1167271",Times;margin:24px 0px 0px;outline:none 0px;padding:0px 0px 0px 36px;color:rgb(0,0,0);font-size:17px"><table style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none 0px;padding:0px"><tbody><tr class="gmail-row" style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none 0px;padding:0px;vertical-align:top;background-color:rgb(240,249,236)"><td class="gmail-wdth" style="border:0px none;font-family:inherit;font-style:inherit;outline:none 0px;padding:3px 36px 3px 6px">Submission Deadline</td><td style="border:0px none;font-family:inherit;font-style:inherit;outline:none 0px;padding:3px 6px">Friday, 20 April 2018</td></tr><tr class="gmail-row" style="border:0px none;font-family:inherit;font-style:inherit;margin:0px;outline:none 0px;padding:0px;vertical-align:top;background-color:rgb(240,249,236)"><td class="gmail-wdth" style="border:0px none;font-family:inherit;font-style:inherit;outline:none 0px;padding:3px 36px 3px 6px">Publication Date</td><td style="border:0px none;font-family:inherit;font-style:inherit;outline:none 0px;padding:3px 6px">September 2018</td></tr></tbody></table></div><p style="border:0px none;font-family:"Minion W08 Regular_1167271",Times;margin:12px 0px;outline:none 0px;padding:0px;line-height:20px;color:rgb(0,0,0);font-size:17px">Papers are published upon acceptance, regardless of the Special Issue publication date.</p><div><div class="gmail-banner_title_bkg_if" style="border:0px none;font-family:"Minion W08 Regular_1167271",Times;margin:0px;outline:none 0px;padding:0px;float:right;color:rgb(0,0,0);font-size:17px"><p class="gmail-banner_title" style="border:0px none;font-family:agencyr;margin:0px 0px 0px 44px;outline:none 0px;padding:0px 11px;color:white;float:right;font-size:30px;height:51px;line-height:56px;white-space:nowrap;background-color:transparent">Impact Factor 2.348</p></div><div><br></div><div><br></div><div><br></div><div>-- <br><div class="gmail_signature"><div dir="ltr"><p><a name="UNIQUE_ID_SafeHtmlFilter__MailAutoSig">Ing. Francesca Miraglia, PhD<br>
<br>
BCLab Brain Connectivity LABoratory for cognitive neurosciences<br>
IRCCS San Raffaele Pisana Roma<br>
<br>
Via Val Cannuta, 247 -  00166 Roma<br>
</a><span style="color:windowtext;text-decoration:none">+39 0652253767</span><br>
+39 3281512811</p>



<p> </p></div></div>
</div></div></div></div>